Invasive Aspergillosis

3
Pipeline Programs
3
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
3 programs
1
2
AmbisomePhase 41 trial
AmbisomePhase 4
AmBisomePhase 33 trials
Active Trials
NCT07357038Recruiting38Est. May 2027
NCT00362544Completed30Est. Mar 2006
NCT00158730Completed800Est. Jan 2005
+1 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker TestingN/A
Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung InfiltratesN/A
IsavuconazoleN/ASmall Molecule1 trial
Active Trials
NCT04550936Completed307Est. Dec 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker TestingN/A1 trial
Active Trials
NCT02104479Unknown200Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Gilead SciencesAmbisome
Gilead SciencesAmBisome
Gilead SciencesAmBisome
Gilead SciencesAmBisome
PfizerIsavuconazole
Heidelberg PharmaDiagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

Clinical Trials (6)

Total enrollment: 1,405 patients across 6 trials

NCT00334412Gilead SciencesAmbisome

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Start: Mar 2004Est. completion: May 200630 patients
Phase 4Completed
NCT00362544Gilead SciencesAmBisome

PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

Start: Oct 2003Est. completion: Mar 200630 patients
Phase 4Completed
NCT00158730Gilead SciencesAmBisome

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Start: Apr 2003Est. completion: Jan 2005800 patients
Phase 3Completed
NCT07357038Gilead SciencesAmBisome

A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis

Start: Sep 2025Est. completion: May 202738 patients
N/ARecruiting
NCT04550936PfizerIsavuconazole

A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.

Start: Mar 2021Est. completion: Dec 2023307 patients
N/ACompleted
NCT02104479Heidelberg PharmaDiagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

Start: Mar 2014Est. completion: Dec 2020200 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,405 patients
3 companies competing in this space